Neurotrophin Receptor Modulators in Neurodegeneration

📖 Wiki Page

therapeutic1605 wordssynced 2026-04-02

Neurotrophin Receptor Modulators in Neurodegeneration

Introduction

...

Neurotrophin Receptor Modulators in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurotrophin Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Neurotrophin</td>
<td>Primary Receptor</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>TrkB</td>
</tr>
<tr>
<td class="label">NGF</td>
<td>TrkA</td>
</tr>
<tr>
<td class="label">NT-3</td>
<td>TrkC</td>
</tr>
<tr>
<td class="label">NT-4</td>
<td>TrkB</td>
</tr>
<tr>
<td class="label">Target</td>
<td>TrkB (agonist)</td>
</tr>
<tr>
<td class="label">Affinity</td>
<td>Ki ~ 320 nM</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Preclinical Data</td>
<td>Extensive in AD, PD, stroke, TBI</td>
</tr>
<tr>
<td class="label">Clinical Status</td>
<td>Phase I complete</td>
</tr>
<tr>
<td class="label">Target</td>
<td>p75NTR (modulator)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Blocks Aβ相互作用 with p75NTR</td>
</tr>
<tr>
<td class="label">Clinical Status</td>
<td>Phase I complete; Phase II in AD</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">NT-181</td>
<td>TrkB agonist</td>
</tr>
<tr>
<td class="label">R13</td>
<td>TrkB agonist</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>TrkB</td>
</tr>
<tr>
<td class="label">TrkB antibodies</td>
<td>TrkB (activator)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Cyclic peptide BDNF mimetics</td>
<td>Designed to activate TrkB</td>
</tr>
<tr>
<td class="label">NGF-derived peptides</td>
<td>Small peptides mimicking NGF activity</td>
</tr>
<tr>
<td class="label">NT-3 mimetics</td>
<td>Promote motor neuron survival</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">7,8-DHF</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">LM11A-31</td>
<td>Phase I complete</td>
</tr>
<tr>
<td class="label">AAV-NGF (CERE-110)</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">BDNF delivery</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">7,8-DHF</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Phase III (failed)</td>
</tr>
<tr>
<td class="label">NT-3</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">LM11A-31</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">7,8-DHF</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">NGF</td>
<td>Phase III (failed)</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Clinical trials</td>
</tr>
</table>

Neurotrophin Receptor Modulators In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Neurotrophin receptor modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting tropomyosin receptor kinase (Trk) and p75NTR (p75 neurotrophin receptor) signaling pathways. These compounds aim to promote neuronal survival, enhance synaptic plasticity, support cholinergic function, and protect against toxic protein aggregates. The neurotrophin system—including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)—plays critical roles in neuronal development, maintenance, and function throughout life. [@longo2014]

Background: The Neurotrophin System

Key Neurotrophins

Receptor Systems

Trk Receptors (TrkA, TrkB, TrkC)

Trk receptors are tyrosine kinase receptors that mediate pro-survival signaling: [@ibanez2012]

TrkA (encoded by NTRK1) — binds NGF
TrkB (encoded by NTRK2) — binds BDNF and NT-4
TrkC (encoded by NTRK3) — binds NT-3

Signaling pathways activated: [@sun2024]

PI3K/Akt pathway → cell survival
MAPK/ERK pathway → neurite outgrowth, synaptic plasticity
PLCγ pathway → calcium signaling, neurotransmitter release

p75NTR Receptor

The p75NTR receptor (also known as TNFRSF16) has complex signaling:

Can mediate pro-survival or pro-apoptotic signals depending on context
Forms co-receptors with Trk receptors (TrkA-p75NTR, TrkB-p75NTR)
Binds precursor neurotrophins (pro-NGF, pro-BDNF) with high affinity
Activates [NF-κB](/entities/nf-kb), JNK, and caspase pathways

Dysregulation in Neurodegeneration

Neurodegenerative diseases are associated with:

Reduced BDNF levels in AD and PD brains
Impaired TrkB signaling
Increased p75NTR expression in vulnerable [neurons](/entities/neurons)
Pro-NGF accumulation in AD

Mechanism of Action

Trk Agonists

Direct Trk Activation

Small molecules that bind and activate Trk receptors
Bypass the need for endogenous neurotrophin binding
Can cross the [blood-brain barrier](/entities/blood-brain-barrier)

BDNF Mimetics

Engineered proteins that mimic BDNF function
Often designed to have improved stability

Allosteric Modulators

Enhance Trk signaling induced by endogenous neurotrophins
May have more physiological activation patterns

Gene Therapy Approaches

AAV-delivered BDNF or NGF
Viral vector-mediated TrkB expression

p75NTR Modulators

p75NTR Antagonists

Block pro-apoptotic signaling from p75NTR
Prevent cell death induced by pro-neurotrophins
LM11A-31 is the lead compound

p75NTR Agonists

Promote pro-survival NF-κB signaling
May enhance Trk signaling in some contexts

Key Therapeutic Compounds

7,8-DHF (7,8-Dihydroxyflavone)

7,8-DHF is a naturally occurring flavonoid and potent TrkB agonist.

Mechanisms:

Activates TrkB autophosphorylation
Inhibits [Aβ](/proteins/amyloid-beta)-induced neuronal death
Improves synaptic plasticity and memory
Reduces neuroinflammation
Promotes [autophagy](/entities/autophagy) of toxic proteins

Evidence:

Reverses cognitive deficits in multiple AD mouse models
Protects dopaminergic neurons in MPTP/6-OHDA models
Reduces infarct size in stroke models
Enhances hippocampal [LTP](/mechanisms/long-term-potentiation)mechanisms/long-term-potentiation)

LM11A-31

LM11A-31 is a small molecule p75NTR modulator developed by PharmatrophiX.

Mechanisms:

Prevents Aβ binding to p75NTR
Blocks pro-apoptotic signaling
Maintains cholinergic neuron function
Reduces dendritic spine loss

Evidence:

Prevents Aβ-induced neurodegeneration in vitro
Improves cognition in AD mouse models
Well-tolerated in Phase I trials

Other Trk-Targeting Compounds

Peptide-Based Approaches

Clinical Evidence by Disease

Alzheimer's Disease

Key studies:

7,8-DHF treatment in 5xFAD mice reduces amyloid plaques and improves cognition
LM11A-31 blocks Aβ-induced dendritic spine loss in hippocampal neurons
NGF gene therapy (CERE-110) showed safety but efficacy was unclear

Parkinson's Disease

Key studies:

7,8-DHF prevents 6-OHDA-induced dopaminergic neuron loss
BDNF gene therapy has been explored but delivery is challenging
GDNF (not a Trk ligand) has been tested with mixed results

Amyotrophic Lateral Sclerosis

Key studies:

BDNF intravenous delivery failed in ALS trials (delivery issues)
AAV-delivered BDNF showing promise in preclinical models
Combination approaches with neurotrophins being explored

Stroke and Traumatic Brain Injury

Key studies:

7,8-DHF administered post-stroke improves functional recovery
BDNF delivery enhances neuroplasticity after TBI

Peripheral Neuropathy

Combination Strategies

Neurotrophin receptor modulators may be combined with:

[Cholinesterase Inhibitors](/entities/cholinesterase-inhibitors)

[Donepezil](/entities/donepezil), [rivastigmine](/entities/rivastigmine), galantamine
Synergistic effects on cholinergic function

Anti-Amyloid Therapies

Monoclonal antibodies ([lecanemab](/entities/lecanemab), donanemab)
Combined targeting of amyloid and neurotrophin pathways

Anti-[Tau](/proteins/tau) Therapies

Tau aggregation inhibitors
Neurotrophins may protect against tau pathology

Other Neurotrophic Factors

GDNF family ligands
IGF-1

Rehabilitation

Exercise enhances BDNF expression
Cognitive training with pharmacological enhancement

Challenges and Limitations

Blood-Brain Barrier

Many neurotrophins do not cross BBB
Small molecule approaches preferred

Receptor Specificity

TrkB agonists may cause side effects
p75NTR has complex signaling

Dosing and Timing

Chronic treatment may be required
Optimal treatment window unclear

Trk Desensitization

Prolonged activation may lead to receptor downregulation
Intermittent dosing may be needed

Research Directions

Novel Approaches

TrkB-Selective Agonists

Avoiding TrkA/TrkC activation
Reducing side effects

Brain-Penetrant Peptides

Cyclic peptides with improved BBB penetration
Stapled peptides for stability

Allosteric Modulators

Enhancing endogenous neurotrophin signaling
More physiological activation

Gene Therapy

AAV-delivered neurotrophins
CRISPR-based approaches

Cell-Based Therapy

Stem cells engineered to secrete neurotrophins
Encapsulated cell devices

Biomarkers

BDNF levels in blood/CSF as response marker
TrkB activation markers
Neuroimaging of synaptic density

Summary

Neurotrophin receptor modulators offer a rational approach to neurodegenerative disease by enhancing pro-survival signaling in vulnerable neurons. 7,8-DHF and LM11A-31 are the most advanced small molecule candidates, with 7,8-DHF showing extensive preclinical promise across AD, PD, and stroke, while LM11A-31 has completed Phase I trials for AD. Challenges include achieving adequate brain penetration, maintaining receptor selectivity, and avoiding desensitization. The field is moving toward combination approaches and gene therapy to enhance efficacy.

External Links

[ClinicalTrials.gov - Neurotrophin Modulators](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=neurotrophin)
[PubMed Collection - Trk Agonists](https://pubmed.ncbi.nlm.nih.gov/?term=TrkB+agonist+neurodegeneration)
[PharmatrophiX - p75NTR Modulators](https://www.pharmatrophix.com)

References

[Jang SW, Liu X, Yepes M, et al, A selective TrkB agonist with potent neurotrophic activity by 7,8-dihydroxyflavone (2010)](https://pubmed.ncbi.nlm.nih.gov/20133810/)

[Longo FM, Yang T, Knowles JK, et al, Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents (2014)](https://pubmed.ncbi.nlm.nih.gov/24413786/)

[Massa SM, Xie Y, Yang T, et al, Small molecule, non-peptide p75NTR ligands prevent Aβ-induced neuronal degeneration and synaptic loss (2010)](https://pubmed.ncbi.nlm.nih.gov/21179087/)

Poduslo JF, Curran GL, Wengenack TM, et al, 7,8-dihydroxyflavone significantly improves blood-brain barrier penetration of dopaminergic neurons (2016)

Liu X, Chan CB, Jang SW, et al, A synthetic 7,8-dihydroxyflavone derivative promotes neurite outgrowth and protects against Aβ toxicity (2010)

Nagahara AH, Tuszynski MH, Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011)

Allen SJ, Watson JJ, Shoemark DK, et al, GDNF, NGF and BDNF as therapeutic options for neurodegeneration (2013)

Chao MV, Neurotrophins and their receptors: A convergence point for many signalling pathways (2003)

Ibanez CF, Simi A, p75 neurotrophin receptor signaling in nervous system injury and degeneration: Paradox and opportunity (2012)

Sun XY, Tully P, Kong Q, et al, Novel small molecule TrkB agonists for the treatment of Alzheimer's disease (2024)

📖 View canonical wiki page →

Neurotrophin Receptor Modulators in Neurodegeneration

Neurotrophin Receptor Modulators in Neurodegeneration

Introduction

Neurotrophin Receptor Modulators in Neurodegeneration

Introduction

Overview

Background: The Neurotrophin System

Key Neurotrophins

Receptor Systems

Trk Receptors (TrkA, TrkB, TrkC)

p75NTR Receptor

Dysregulation in Neurodegeneration

Mechanism of Action

Trk Agonists

p75NTR Modulators

Key Therapeutic Compounds

7,8-DHF (7,8-Dihydroxyflavone)

LM11A-31

Other Trk-Targeting Compounds

Peptide-Based Approaches

Clinical Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Stroke and Traumatic Brain Injury

Peripheral Neuropathy

Combination Strategies

Challenges and Limitations

Research Directions

Novel Approaches

Biomarkers

Summary

See Also

External Links

References